2026-04-19T23:49:14Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/57032021-11-02T12:01:28Zcom_10259_3924com_10259_5086com_10259_2604col_10259_3925

Martínez García, David 18e02fd6-ef02-4fc0-a41e-ce87d3ba38c1 500 Manero Rupérez, Noemí 0a87c433-e962-4faa-8a71-c1ec688cadb7 500 Quesada Pato, Roberto 458 500 Korrodi Gregório, Luís 458f34b5-7c73-488a-b503-a98a3dd637b3 500 Soto Cerrato, Vanessa 346bb3c7-0c69-4d62-9045-26b0b8d37a51 500 2021-04-13T10:30:17Z 2021-04-13T10:30:17Z 2019-05 0198-6325 http://hdl.handle.net/10259/5703 10.1002/med.21547 1098-1128 Survivin is a small protein that belongs to the inhibitor of apoptosis protein family. It is abundantly expressed in tumors compared with adult differentiated tissues, being associated with poor prognosis in many human neoplasms. This apoptotic inhibitor has a relevant role in both the promotion of cancer cell survival and in the inhibition of cell death. Consequently, aberrant survivin expression stimulates tumor progression and confers resistance to several therapeutic strategies in a variety of tumors. In fact, efficient survivin downregulation or inhibition results in spontaneous apoptosis or sensitization to chemotherapy and radiotherapy. Therefore, all these features make survivin an attractive therapeutic target to treat cancer. Currently, there are several survivin inhibitors under clinical evaluation, although more specific and efficient survivin inhibitors are being developed. Moreover, novel combination regimens targeting survivin together with other therapeutic approaches are currently being designed and assessed. In this review, recent progress in the therapeutic options targeting survivin for cancer treatment is analyzed. Direct survivin inhibitors and their current development status are explored. Besides, the major signaling pathways implicated in survivin regulation are described and different therapeutic approaches involving survivin indirect inhibition are evaluated. Finally, promising novel inhibitors under preclinical or clinical evaluation as well as challenges of developing survivin inhibitors as a new therapy for cancer treatment are discussed. Consejería de Educación, Junta de Castilla y León. Grant Number: BU092U16 Instituto de Salud Carlos III. Grant Number: FIS PI18/00441 application/pdf eng Wiley Medicinal Research Reviews. 2019, V. 39, n. 3, p. 887-909 https://doi.org/10.1002/med.21547 info:eu-repo/grantAgreement/JCyL/BU092U16 anticancer therapy apoptosis chemoresistance inhibitor ofapoptosis proteins SMAC mimetics survivin inhibitors Química orgánica Chemistry, Organic Therapeutic strategies involving survivin inhibition in cancer info:eu-repo/semantics/article info:eu-repo/semantics/submittedVersion info:eu-repo/semantics/openAccess Medicinal Research Reviews 39 3 887 909 ORIGINAL Martinez-mrr_2019.pdf Martinez-mrr_2019.pdf application/pdf 922660 https://riubu.ubu.es/bitstream/10259/5703/1/Martinez-mrr_2019.pdf e4b61716cdb405a239906646577455d5 MD5 1 LICENSE license.txt license.txt text/plain; charset=utf-8 999 https://riubu.ubu.es/bitstream/10259/5703/2/license.txt b295bcbce42e2caabeb0c623d3860c06 MD5 2 THUMBNAIL Martinez-mrr_2019.pdf.jpg Martinez-mrr_2019.pdf.jpg IM Thumbnail image/jpeg 3982 https://riubu.ubu.es/bitstream/10259/5703/3/Martinez-mrr_2019.pdf.jpg bbde2ffa09b16f10513c755f04d78a61 MD5 3 10259/5703 oai:riubu.ubu.es:10259/5703 2021-11-02 13:01:28.451 Repositorio Institucional de la Universidad de Burgos bubrep@ubu.es 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